Effect of niacin on FGF23 concentration in chronic kidney disease

American Journal of Nephrology

Volumn 39, Issue 6, 2014, Pages 484-490

  Rao, Madhumathi ^a   Steffes, Michael ^b   Bostom, Andrew ^c   Ix, Joachim H ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Calcium; Cardiovascular disease; Growth factor; Kidney disease; Niacin; Phosphorus

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; ANTILIPEMIC AGENT; DELAYED RELEASE FORMULATION; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN RECEPTOR; INDOLE DERIVATIVE; MK-0524; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; LAROPIPRANT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; CALCIUM BLOOD LEVEL; DRUG EFFECT;

AGED; CALCIUM; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; MIDDLE AGED; NIACIN; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84900890448     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000362424     Document Type: Article

References (44)

1. Kendrick J, Kestenbaum B, Chonchol M: Phosphate and cardiovascular disease. Adv Chronic Kidney Dis 2011; 18: 113-119.
2. Gutierrez OM: Fibroblast growth factor-23 and disordered vitamin d metabolism in chronic kidney disease: updating the 'tradeoff' hypothesis. Clin J Am Soc Nephrol 2010.
3. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435.
4. Wolf M: Update on fibroblast growth factor- 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
5. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, et al: Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
6. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al: Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
7. Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390.
8. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, et al: Elevated fibroblast growth factor-23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
9. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, et al: Fibroblast growth factor- 23 predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
10. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, et al: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415.
11. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571.
12. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, Wolf M: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor-23 in patients with chronic kidney disease. Nephrol Dial Transplant 2010; 26: 584-591.
13. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKDMBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
14. Ahmed MH: Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. Ren Fail 2010; 32: 642-646.
15. Bostom AG: Binder blinders-niacin of omission? Am J Kidney Dis 2010; 55: 628-630.
16. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN: Extended release nicotinic acid -a novel oral agent for phosphate control. Int Urol Nephrol 2006; 38: 171-174.
17. Eto N, Miyata Y, Ohno H, Yamashita T: Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20: 1378-1384. (Pubitemid 41430611)
18. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K, et al: Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14: 1195-1201. (Pubitemid 29209307)
19. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1131-1138.
20. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz R: Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007; 2: 1249-1254.
21. Bostom AG, Maclean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA: Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. J Clin Lipidol 2011; 5: 281-287.
22. Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG: Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 2011; 57: 963-965.
23. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG: Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010; 5: 582-589.
24. Hu S, Shearer GC, Steffes MW, Harris WS, Bostom AG: Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Am J Kidney Dis 2011; 57: 181-182.
25. Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, et al: Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62: 1959-1970.
26. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, et al: Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625-630.
27. Kaijser L, Eklund B, Olsson AG, Carlson LA: Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979; 57: 114-117. (Pubitemid 9187410)
28. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):S1-S201.
29. Levey AS, Stevens LA: Estimating GFR using the CKD Epidemiology Collaboration (CKDEPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55: 622-627.
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
31. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 200-207.
32. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
33. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 56: 842-851.
34. Markel A: The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. Isr Med Assoc J 2011; 13: 368-374.
35. Asano S, Suzuki A, Sekiguchi S, Nishiwaki- Yasuda K, Shibata M, Itoh M: Effects of prostaglandin D 2 on Na-dependent phosphate transport activity and its intracellular signaling mechanism in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 247-251.
36. Durand M, Gallant MA, de Brum-Fernandes AJ: Prostaglandin D 2 receptors control osteoclastogenesis and the activity of human osteoclasts. J Bone Miner Res 2008; 23: 1097-1105. (Pubitemid 351915732)
37. Yue L, Durand M, Lebeau Jacob MC, Hogan P, McManus S, Roux S, de Brum-Fernandes AJ: Prostaglandin D 2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone 2012; 51: 338-346.
38. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y: Parathyroid hormone regulates fibroblast growth factor- 23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688. (Pubitemid 47531195)
39. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ: Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24: 842-852.
40. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al: Fibroblast growth factor-23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
41. Dhingra R, Gona P, Benjamin EJ, Wang TJ, Aragam J, D'Agostino RB Sr, Kannel WB, Vasan RS: Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 2010; 12: 812-818.
42. Foley RN, Collins AJ, Ishani A, Kalra PA: Calcium- phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008; 156: 556-563.
43. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
44. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633. (Pubitemid 41532599)